Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro

Owen,Sioned; Sanders,Andrew   J.; Mason,Malcolm  D.; Jiang,Wen  G.

doi:10.3892/ijo.2016.3339

Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro

Authors:
- Sioned Owen
- Andrew J. Sanders
- Malcolm D. Mason
- Wen G. Jiang
View Affiliations

Affiliations: Cardiff China Medical Research Collaborative, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK, Section of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK
Published online on: January 15, 2016 https://doi.org/10.3892/ijo.2016.3339
Pages: 919-928
Copyright: © Owen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteoprotegrin (OPG), receptor activator of nuclear factor κB (RANK) and RANK ligand (RANKL) are signal transducers which have pleiotropic actions. Each tumour necrosis factor receptor superfamily member has unique structural attributes which directly couples them to signalling pathways involved in cell proliferation, differentiation and survival. Previous studies have clinically linked OPG, RANK and RANKL to increasing tumour burden, metastatic bone involvement and estrogen status. This study aimed to establish the potential implications of targeting endogenously produced OPG and RANK in the osteotropic breast cancer cell line MDA-MB‑231 in vitro. Subsequently this study also aimed to explore the potential links between these molecules with regards to hepatocyte growth factor (HGF) signalling and extracted bone proteins (BME). OPG and RANK expression was successfully suppressed using hammerhead ribozyme technology. Subsequently effects were explored in MDA-MB‑231 cell proliferation, matrix adhesion, migration and invasion in vitro function assays. Reduced OPG expression resulted in increased breast cancer cell migration and invasion. These increases, particularly invasion, appeared to however be reduced under the influence of the exogenous stimuli (HGF and BME). In contrast, suppression of RANK in MDA-MB‑231 breast cancer cells resulted in decreased cancer cell proliferation, matrix-adhesion, motility and invasion with little cumulative effect being noted after the addition of exogenous stimuli. The complexity of the bone environment underpins the vast number of soluble factors and signalling pathways which can influence osteotropic cancer behaviour and progression. Further work into elucidating all the pathways affected could potentially lead to better identification of those patients most at risk.

View Figures

View References

1	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:S6243–S6249. 2006. View Article : Google Scholar
2	Roodman GD: Mechanisms of bone metastasis. N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
3	Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
4	Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8:98–101. 1989.PubMed/NCBI
5	Siclari VA, Guise TA and Chirgwin JM: Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 25:621–633. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fidler IJ and Poste G: The ‘seed and soil’ hypothesis revisited. Lancet Oncol. 9:8082008. View Article : Google Scholar
7	Weilbaecher KN, Guise TA and McCauley LK: Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425. 2011. View Article : Google Scholar : PubMed/NCBI
8	Boyce BF and Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
9	Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, Miyata T and Kumegawa M: Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun. 251:796–801. 1998. View Article : Google Scholar : PubMed/NCBI
10	Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1329–1337. 1998.PubMed/NCBI
11	Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, et al: Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clin Breast Cancer. 11:369–375. 2011. View Article : Google Scholar : PubMed/NCBI
12	Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, et al: Bone metastases detection by circulating biomarkers: OPG and RANK-L. Int J Oncol. 39:255–261. 2011.PubMed/NCBI
13	Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE and Holen I: Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol. 59:56–63. 2006. View Article : Google Scholar : PubMed/NCBI
14	Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE and Holen I: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 86:269–279. 2004. View Article : Google Scholar : PubMed/NCBI
15	Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE and Eaton CL: Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival? Breast Cancer Res Treat. 92:207–215. 2005. View Article : Google Scholar : PubMed/NCBI
16	Nicolin V and Narducci P: Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem. 112:189–192. 2010. View Article : Google Scholar
17	Michalopoulos G, Houck KA, Dolan ML and Leutteke NC: Control of hepatocyte replication by two serum factors. Cancer Res. 44:4414–4419. 1984.PubMed/NCBI
18	Nakamura T, Nawa K and Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 122:1450–1459. 1984. View Article : Google Scholar : PubMed/NCBI
19	Russell WE, McGowan JA and Bucher NL: Biological properties of a hepatocyte growth factor from rat platelets. J Cell Physiol. 119:193–197. 1984. View Article : Google Scholar : PubMed/NCBI
20	Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 53:35–69. 2005. View Article : Google Scholar
21	Parikh RA, Wang P, Beumer JH, Chu E and Appleman LJ: The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 7:969–983. 2014.PubMed/NCBI
22	Davies S and Jiang WG: ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res. 30:1163–1168. 2010.PubMed/NCBI
23	Sanders AJ, Parr C, Mason MD and Jiang WG: Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med. 20:613–619. 2007.PubMed/NCBI
24	Yuan Z, Sanders AJ, Ye L, Wang Y and Jiang WG: Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep. 26:237–245. 2011.PubMed/NCBI
25	Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
26	Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE and Puntis MC: Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res. 55:5043–5048. 1995.PubMed/NCBI
27	Jiang WG, Hiscox S, Singhrao SK, Nakamura T, Puntis MC and Hallett MB: Inhibition of HGF/SF-induced membrane ruffling and cell motility by transient elevation of cytosolic free Ca²⁺. Exp Cell Res. 220:424–433. 1995. View Article : Google Scholar : PubMed/NCBI
28	Rosen EM, Carley W and Goldberg ID: Scatter factor regulates vascular endothelial cell motility. Cancer Invest. 8:647–650. 1990. View Article : Google Scholar : PubMed/NCBI
29	Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47:3239–3245. 1987.PubMed/NCBI
30	Parish CR, Jakobsen KB and Coombe DR: A basement-membrane permeability assay which correlates with the metastatic potential of tumour cells. Int J Cancer. 52:378–383. 1992. View Article : Google Scholar : PubMed/NCBI
31	Owen S, Ye L, Sanders AJ, Mason MD and Jiang WG: Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 33:199–206. 2013.
32	Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR Jr and Gonzalez-Angulo AM: cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 18:2269–2277. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zinonos I, Luo KW, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ko CH, Yue GG, Lau CB, et al: Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. Int J Oncol. 45:532–540. 2014.PubMed/NCBI
34	Weichhaus M, Segaran P, Renaud A, Geerts D and Connelly L: Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis. Cancer Med. 3:1112–1125. 2014. View Article : Google Scholar : PubMed/NCBI
35	Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, et al: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 97(Suppl): 887–892. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, Reddy VV and Ponnazhagan S: Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther. 16:871–878. 2008. View Article : Google Scholar : PubMed/NCBI
37	Blake ML, Tometsko M, Miller R, Jones JC and Dougall WC: RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis. 31:233–245. 2014. View Article : Google Scholar
38	Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, et al: RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One. 8:e631532013. View Article : Google Scholar : PubMed/NCBI